Evidence map›Paper›PMID 20705755›Full record

Trial reportBlood2010

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

Bayard L Powell, Barry Moser, Wendy Stock, Robert E Gallagher, Cheryl L Willman, Richard M Stone, Jacob M Rowe, Steven Coutre, James H Feusner, John Gregory and 4 more

3 registry-linked trialsOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 158 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 5 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00003934 phase3completednot on this map

Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mercaptopurine and Methotrexate for Patients With Untreated Acute Promyelocytic Leukemia

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran1999Enrolled420ConditionsAdult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Promyelocytic Leukemia (M3)Armstretinoin, daunorubicin hydrochloride, cytarabine, mercaptopurine, methotrexate
NCT04251754 unknown statusnot on this mapstarted 2020, after this paper: background citation

The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project

TypeobservationalSponsorThe University of Hong KongRan2020 to 2025Enrolled1,000ConditionsAcute Promyelocytic Leukemia
NCT04562818 completednot on this map

Results From a Mexican Long-term Multicentric Study on Acute Promyelocytic Leukemia.

TypeobservationalSponsorInstituto Nacional de Cancerologia de MexicoRan2007 to 2018Enrolled360ConditionsPromyelocytic Leukemia, AcuteArmsDiagnosis, Molecular and Karyotype, Leucocytes
3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 5 syntheses or guidelines pooled it, 398 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Acute myeloid leukemia, version 2.2013.Journal of the National Comprehensive Cancer Network : JNCCN · 2013
    Guideline
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  10. Trial
  11. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).Proceedings of the National Academy of Sciences of the United States of America · 2021
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Bayard L PowellCancer and Leukemia Group B, Chicago IL, USA. bpowell@wfubmc.edu
Barry Moser
Wendy Stock
Robert E Gallagher
Cheryl L Willman
Richard M Stone
Jacob M Rowe
Steven Coutre
James H Feusner
John Gregory
Stephen Couban
Frederick R Appelbaum
Martin S Tallman
Richard A Larson
Leukemia Research Foundation · USEastern Cooperative Oncology Group · USSWOG Cancer Research Network · USArcadia · USOntario Institute for Cancer Research · CA

Funding

CANCER AND LEUKEMIA GROUP B MINORITY SATELLITE SUPPLEMENU10CA031946 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 1985 to 2013
$158.4M
CANCER &LEUKEMIA GROUP B STATISTICAL CENTERU10CA033601 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SARGENT, DANIEL J. · 1985 to 2013
$69.4M
NCI NIH HHS CA31946NCI NIH HHS CA33601NCI NIH HHS U10 CA031946NCI NIH HHS U10 CA033601
6 · The paper itself

Abstract

Arsenic trioxide (As(2)O(3)) is a highly effective treatment for patients with relapsed acute promyelocytic leukemia (APL); its role as consolidation treatment for patients in first remission has not been defined. We randomized 481 patients (age ≥ 15 years) with untreated APL to either a standard induction regimen of tretinoin, cytarabine, and daunorubicin, followed by 2 courses of consolidation therapy with tretinoin plus daunorubicin, or to the same induction and consolidation regimen plus two 25-day courses of As(2)O(3) consolidation immediately after induction. After consolidation, patients were randomly assigned to one year of maintenance therapy with either tretinoin alone or in combination with methotrexate and mercaptopurine. Ninety percent of patients on each arm achieved remission and were eligible to receive their assigned consolidation therapy. Event-free survival, the primary end point, was significantly better for patients assigned to receive As(2)O(3) consolidation, 80% compared with 63% at 3 years (stratified log-rank test, P < .0001). Survival, a secondary end point, was better in the As(2)O(3) arm, 86% compared with 81% at 3 years (P = .059). Disease-free survival, a secondary end point, was significantly better in the As(2)O(3) arm, 90% compared with 70% at 3 years (P < .0001). The addition of As(2)O(3) consolidation to standard induction and consolidation therapy significantly improves event-free and disease-free survival in adults with newly diagnosed APL. This trial was registered at clinicaltrials.gov (NCT00003934).

Indexed as

AdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsArsenicalsArsenic TrioxideCytarabineDaunorubicinDisease-Free SurvivalFemaleHumansLeukemia, Promyelocytic, AcuteMaleMercaptopurineMethotrexateMiddle AgedArsenicalsArsenic TrioxideCytarabineDaunorubicinMercaptopurineMethotrexateOxidesTretinoin

Identifiers

PMID20705755
PMCPMC2981533
OpenAlexW2089988981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.